Timothy J. Obara

Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey.

CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT.

Italfarmaco SpA engages in the production and distribution of pharmaceutical and fine chemical products. It also provides research and development, scientific publishing, business development, and licensing services. The company was founded in 1938 and is headquartered in Milan, Italy.

Axon Partners Group Investment SGEIC SA (Axon Partners Group) is a private equity and venture capital firm founded in 2006 by Julio Villalobos Rius. The firm is headquartered in Madrid, Spain with offices across the globe.

Xyence Capital SGR (Xyence Capital) is a venture capital firm founded in 2002 by Stefano Peroncini and Pierluigi Paracchi. The firm is headquartered in Milano, Italy.

BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart.

Part of McKinsey & Co., Inc., McKinsey & Co., Inc. (United Kingdom) is a consulting firm that helps UK manufacturers embrace new technologies for digital transformation and leadership. The company is based in London, UK. Ruben Schaubroeck, McKinsey Digital's new lead for the UK, Belgium, and Netherlands offices, spoke with Thomas Farrar, a manager of communications in the firm's UK office, about the importance of speed and pace for CEOs in this new growth journey. The British company works with organizations that pursue sustainability, inclusion, and economic growth, all at the same time, to achieve strategic foresight and built-in agility in the face of the COVID-19 pandemic and the new trading relationship with the EU.

Zambon SpA is engaged in manufacturing pharmaceutical products. It offers anauran, anaurette, asacol, codex, fluimucil, and giason. The company is headquartered in Bresso, Italy.

Novartis UK Ltd. is an international pharmaceutical company. It strives to discover ways to improve and extend people’s lives. The company is headquartered in Frimley, the United Kingdom.

Sandoz SpA manufactures pharmaceutical products. It develops and distributes medicines for cardiovascular systems, antibiotics, antidepressants, anti-asthmatics, calcium compounds, and laxatives. The company is headquartered in Origgio, Italy.

Elanco Italia SpA operates as a global health company. It provides products, services and knowledge to prevent and treat farmed and companion animal diseases in more than 90 countries. The company is headquartered in Sesto Fiorentino, Italy.

Novartis Norge AS develops, markets, and trades pharmaceuticals. It offers ophthalmic and generic products. The company is headquartered in Oslo, Norway.

Assobiotec is an organization that represents approximately 130 companies and technological and scientific parks in the biotech sector. Assobiotec is based in Milan, Italy. The Italian company focuses on various areas such as health, agriculture, environment, and industrial processes. The private company was founded in 1986, and the CEO is Leonardo Vingiani.

Tethis SpA engages in the provision of nanobiotechnology solutions. It develops devices for liquid biopsy, molecular diagnostic, and proteomic and microbiology. The company was founded by Emanuele Barborini, Simone Vinati, and Massimo Gatelli in 2004 and is headquartered in Milan Italy.

Biological Dynamics, Inc. engages in the development of cancer diagnostic solutions for labs and homes. Its platform offers a way to isolate cell-free nanoparticles and macromolecules directly from whole blood, serum, or plasma. The firm also develops a suite of oncology tests for early cancer detection, treatment response, and recurrence monitoring. The company was founded by Raj Krishnan, Edward D. Truitt III, Michael J. Heller, Roy Lefkowitz, and David Charlot in 2008 and is headquartered in San Diego, CA.

The American Society of Gene & Cell Therapy is a medical and professional organization that represents researchers and scientists devoted to the discovery of gene and cell therapies. The American company was founded by Mark A. Kay.

Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland.

Digitail SRL provides software solutions for electronic commerce. It develops the mobile application brand EasyCoop which enables online ordering of grocery items for delivery. The company was founded by Marco Di Falco in 2016 and is headquartered in Castenaso, Italy.

Lipogems International SpA engages in the provision of adipose tissue solutions for pathologies, orthopedics, general surgery, and wound care. It offers Lipogems system, a sterile single –use medical device for the closed-loop processing and transferring of autologous adipose tissue in a single surgical step. The company was founded by Carlo Tremolada in 2010 and is headquartered in Milan, Italy.

Altheia Science Srl develop treatment and resolving medicines for auto-immune diseases, focusing on multiple sclerosis and diabetes. The company was founded by Paolo Fiorina, Alessandra Biffi, Paolo Rizzardi, and is headquartered in Milan, Italy.

Aurora-TT Srl (AuroraTT) is an independent venture capital firm.. Guido Guidi, Gabriele Campi, Pierluigi Paracchi, Gian Paolo Maria Rizzardi and Edoardo Negroni founded the firm in 2017. The firm is headquartered in Milan, Italy.

GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy.

Epsilen Bio SRL operates as a biotechnology company. It develops novel therapies based on epigenetic silencing. The company was founded by Angelo Lombardo and Luigi Naldini in December 2019 and is headquartered in Milan, Italy.

Aurora Science, invests in Italian startups. The fund invests in health technology with particular interest for biotech and pharmaceuticals. It provides equity financing for early stage investing between EUR 1 to EUR 5 million.

Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020.